Loading
A phase 3 trial of ASP-1929 Photoimmunotherapy in head and neck squamous cell carcinoma, run by Rakuten Medical, Inc., active and no longer recruiting.
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy is a phase 3 interventional study registered as NCT03769506 by Rakuten Medical, Inc., with 135 participants enrolled, started 2019-05-09 and due to reach its primary completion in 2025-12. Interventions recorded: ASP-1929 Photoimmunotherapy and Physician's Choice SOC.
Shares Rakuten Medical, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.